| 摘要 |
<p>The invention describes the use of vasopeptidase inhibitors of the formula ( I) for the treatment and/or prophylaxis of nephropathy in diabetic or non- diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistence or of metabolic diseases associated with advanced glycation end- products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and/or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.</SDO AB></p> |
